Johnson & Johnson.
1Q Revenues: $17.5 billion (+1%)
1Q Earnings: $4.9 billion (+1%)
Comments: Pharmaceutical sales were $8.2 billion in the quarter, up 6%, with domestic sales up 13% and international sales down 3%. REMICADE sales were $1.8 billion in the quarter, up 11%. SIMPONI/SIMPONI ARIA sales were $390 million, up 30%. STELARA sales were $735 million, up 34%. INVEGA SUSTENNA/XEPLION/TRINZA sales were $513 million, up 25%. New product sales growth was negatively impacted by lower sales of OLYSIO/SOVRIAD (simeprevir) down 86% to $32 million due to competitive Hep C entrants. Growth in new products include: IMBRUVICA with $261 million in sales, approved for certain B-cell malignancies; XARELTO (+29% to $567 million), an oral anticoagulant; and INVOKANA/INVOKAMET (+17% to $325 million), for the treatment of type 2 diabetes.